HUE034876T2 - Cirkadián ritmussal kapcsolatos rendellenességek kezelése - Google Patents

Cirkadián ritmussal kapcsolatos rendellenességek kezelése Download PDF

Info

Publication number
HUE034876T2
HUE034876T2 HUE13703254A HUE13703254A HUE034876T2 HU E034876 T2 HUE034876 T2 HU E034876T2 HU E13703254 A HUE13703254 A HU E13703254A HU E13703254 A HUE13703254 A HU E13703254A HU E034876 T2 HUE034876 T2 HU E034876T2
Authority
HU
Hungary
Prior art keywords
patient
melatonin
sleep
day
hours
Prior art date
Application number
HUE13703254A
Other languages
English (en)
Hungarian (hu)
Inventor
Marlene Michelle Dressman
John Joseph Feeney
Louis William Licamele
Mihael H Polymeropoulos
Original Assignee
Vanda Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47679075&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUE034876(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Vanda Pharmaceuticals Inc filed Critical Vanda Pharmaceuticals Inc
Publication of HUE034876T2 publication Critical patent/HUE034876T2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/62—Detectors specially adapted therefor
    • G01N30/72—Mass spectrometers
    • G01N30/7233—Mass spectrometers interfaced to liquid or supercritical fluid chromatograph
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2864—Sleep disorders
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Medical Informatics (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Anesthesiology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Data Mining & Analysis (AREA)
  • Primary Health Care (AREA)
HUE13703254A 2012-01-26 2013-01-25 Cirkadián ritmussal kapcsolatos rendellenességek kezelése HUE034876T2 (hu)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US201261590974P 2012-01-26 2012-01-26
US201261640067P 2012-04-30 2012-04-30
US201261650458P 2012-05-22 2012-05-22
US201261650455P 2012-05-22 2012-05-22
US201261714149P 2012-10-15 2012-10-15
US201261738985P 2012-12-18 2012-12-18
US201261738987P 2012-12-18 2012-12-18
US201361755896P 2013-01-23 2013-01-23

Publications (1)

Publication Number Publication Date
HUE034876T2 true HUE034876T2 (hu) 2018-03-28

Family

ID=47679075

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE13703254A HUE034876T2 (hu) 2012-01-26 2013-01-25 Cirkadián ritmussal kapcsolatos rendellenességek kezelése

Country Status (21)

Country Link
US (22) US8785492B2 (https=)
EP (5) EP3300728A3 (https=)
JP (10) JP2015509106A (https=)
KR (10) KR102171965B1 (https=)
CN (4) CN111603460A (https=)
AU (9) AU2013211880A1 (https=)
BR (2) BR112014018429A8 (https=)
CA (4) CA3159064A1 (https=)
CL (2) CL2014001992A1 (https=)
CO (2) CO7131366A2 (https=)
DK (1) DK2806863T3 (https=)
ES (2) ES2897671T3 (https=)
HR (1) HRP20171600T1 (https=)
HU (1) HUE034876T2 (https=)
IL (4) IL233714A0 (https=)
IN (2) IN2014DN07050A (https=)
MX (4) MX374068B (https=)
PT (1) PT2806863T (https=)
RU (2) RU2650647C2 (https=)
SI (1) SI2806863T1 (https=)
WO (2) WO2013112951A2 (https=)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2488392C2 (ru) * 2006-05-22 2013-07-27 Ванда Фармасьютиклз, Инк. Лечение агонистом мелатонина
US9532952B2 (en) 2011-01-28 2017-01-03 Physician's Seal, LLC Controlled-release compositions of melatonin combined with sedative and/or analgesic ingredients
US8691275B2 (en) 2011-01-28 2014-04-08 Zx Pharma, Llc Controlled-release melatonin compositions and related methods
WO2013112951A2 (en) 2012-01-26 2013-08-01 Vanda Pharmaceuticals Inc. Treatment of circadian rhythm disorders
US11918557B2 (en) 2012-01-26 2024-03-05 Vanda Pharmaceuticals Inc. Treatment of circadian rhythm disorders
BR112014028446A2 (pt) 2012-05-18 2017-10-24 Vanda Pharmaceuticals Inc composto isolado, composição farmacêutica, método de tratamento ou prevenção de pelo menos um de doenças, distúrbios ou condições seguintes, e, método de tratamento ou prevenção de um distúrbio de ritmo circadiano ou distúrbio com um componente circadiano em um indivíduo
KR102148990B1 (ko) * 2012-12-18 2020-08-27 반다 파마슈티칼즈, 인코퍼레이티드. 일주기 리듬 장애의 치료
US11090285B2 (en) 2013-11-12 2021-08-17 Vanda Pharmaceuticals Inc Treatment of circadian rhythm disorders
US10376487B2 (en) 2013-11-12 2019-08-13 Vanda Pharmaceuticals Inc. Method of treatment
WO2015117048A1 (en) * 2014-01-31 2015-08-06 Vanda Pharmaceuticals Inc. Treatment of circadian rhythm disorders
ES2936833T3 (es) * 2014-09-02 2023-03-22 Vanda Pharmaceuticals Inc Tasimelteón para tratar síndrome de Smith-Magenis
US10076286B1 (en) 2014-10-21 2018-09-18 Verily Life Sciences Llc Methods and devices for circadian rhythm monitoring
WO2016109359A1 (en) * 2014-12-29 2016-07-07 Auspex Pharmaceuticals, Inc. Cyclopropyl dihydrobenzofuran modulators of melatonin receptors
US11013713B2 (en) * 2015-12-15 2021-05-25 Vanda Pharmaceuticals Inc. Method of treatment
TW201726617A (zh) 2016-01-06 2017-08-01 奧斯佩生物製藥公司 Ｓｉｒｔ１受體的四氫咔唑抑制劑
KR20190008265A (ko) 2016-05-06 2019-01-23 피지션즈 씰, 엘엘씨 발레리안 조성물 및 관련 방법
WO2018033546A1 (en) * 2016-08-18 2018-02-22 Koninklijke Philips N.V. Blood-pressure management
US20210059973A1 (en) * 2017-08-02 2021-03-04 Vanda Pharmaceuticals Inc. Treatment of Affective Disorders
KR20200119296A (ko) * 2018-03-04 2020-10-19 반다 파마슈티칼즈, 인코퍼레이티드. 타시멜테온을 이용한 질환의 치료
US11346169B2 (en) 2018-07-23 2022-05-31 Kobold Corporation Sleeve valves, shifting tools and methods for wellbore completion operations therewith
CN108828098B (zh) * 2018-07-24 2020-04-21 山东农业大学 一种高效液相色谱-质谱法测定棉花中褪黑素的方法
CN113365618A (zh) * 2018-09-12 2021-09-07 万带兰制药公司 改善睡眠或睡醒后表现
KR102260252B1 (ko) * 2018-10-24 2021-06-03 주식회사 인코스팜 피부 세포를 통한 일주기 리듬 분석 방법, 일주기 리듬 장애를 정상화하는 방법 및 일주기 리듬 정보를 이용한 정보제공 시스템
CN109522688B (zh) * 2018-10-27 2023-10-13 平安医疗健康管理股份有限公司 基于数据处理的肾功能衰竭资质认证方法、设备及服务器
EP3671757A1 (en) * 2018-12-18 2020-06-24 Koninklijke Philips N.V. System and method for determining a level of alertness
ES3020034T3 (en) * 2019-06-29 2025-05-21 Vanda Pharmaceuticals Inc Tasimelteon use in treating sleep aberrations
JP7276787B2 (ja) * 2019-11-25 2023-05-18 株式会社村田製作所 解析システム及び解析方法
EP4072542A1 (en) 2019-12-13 2022-10-19 Vanda Pharmaceuticals Inc. Liquid tasimelteon formulations and methods of use thereof

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL50699A0 (en) 1975-10-28 1976-12-31 Ici America Inc Triazole derivatives
DE3466215D1 (en) 1983-05-18 1987-10-22 Univ Monash The use of melatonin for the manufacture of a medicament
IL79264A0 (en) 1986-06-27 1986-09-30 Univ Ramot Tryptamine derivatives,pharmaceutical compositions containing them and their use in an assay for melatonin receptors
US4997845A (en) 1987-02-02 1991-03-05 Eli Lilly And Company β-alkylmelatonins as ovulation inhibitors
US5093352A (en) 1988-11-14 1992-03-03 Whitby Research, Inc. Antidepressant agents
US5151446A (en) 1989-09-25 1992-09-29 Northwestern University Substituted 2-amidotetralins as melatonin agonists and antagonists
FR2658818B1 (fr) 1990-02-27 1993-12-31 Adir Cie Nouveaux derives a structure naphtalenique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
US5242941A (en) 1990-12-04 1993-09-07 State Of Oregon Methods of treating circadian rhythm disorders
US6638963B1 (en) * 1990-12-04 2003-10-28 Oregon Health And Science University Methods for treating circadian rhythm disorders
IT1251544B (it) 1991-05-13 1995-05-17 Gabriele Biella Composizioni farmaceutiche attive nella terapia dei disturbi del sonno comprendenti melatonina o un suo derivato in associazione con un derivato benzodiazepinico
US6180657B1 (en) 1993-11-18 2001-01-30 Eli Lilly And Company Melatonin derivatives for use in treating desynchronization disorders
US5403851A (en) 1994-04-05 1995-04-04 Interneuron Pharmaceuticals, Inc. Substituted tryptamines, phenalkylamines and related compounds
GB9416884D0 (en) 1994-08-20 1994-10-12 Danbiosyst Uk Drug delivery compositions
MD1716C2 (ro) * 1995-02-01 2002-02-28 Neurim Pharmaceuticals (1991) Ltd. Utilizare a melatoninei pentru tratamentul pacienţilor dependenţi de benzodiazepine
CA2235803A1 (en) 1995-10-24 1997-05-01 The Trustees Of The University Of Pennsylvania Method of adjusting the circadian rhythm of a mammal
PT1027043E (pt) 1996-12-10 2005-02-28 Bristol Myers Squibb Co Benzodioxole benzofurano di-hidrobenzofurano e benzodioxano como agentes melatonergicos
US5776969A (en) 1997-02-27 1998-07-07 Eli Lilly And Company Treatment of sleep disorders
AUPO588297A0 (en) * 1997-03-26 1997-04-24 Luminis Pty Limited Mediation in melatonin production
JP3055884B2 (ja) 1997-08-07 2000-06-26 花野商事株式会社 引きクランプ装置
DE69910795T2 (de) 1998-06-09 2004-06-17 Takeda Chemical Industries, Ltd. Pharmazeutische kombination mit einer trizyclischen verbindung und mindestens einer von zolpidem, zopiclone und brotizolam, zur behandlung oder verhinderung von schlafstörungen
US6562858B2 (en) 1999-05-17 2003-05-13 St. Elizabeth's Medical Center Of Boston, Inc. Method for treating depression
EP1189900B1 (en) 1999-06-30 2004-01-14 Bristol-Myers Squibb Company Heterocyclic aminopyrrolidine derivatives as melatonergic agents
ES2436439T3 (es) 2001-10-30 2014-01-02 Novartis Ag Formulaciones de medicamento de liberación lenta de iloperidona con un polímero
GB0216416D0 (en) 2002-07-15 2002-08-21 Novartis Ag Organic compounds
IL155666A (en) 2003-04-29 2013-12-31 Neurim Pharma 1991 Insomnia treatment
JP2005080603A (ja) * 2003-09-10 2005-03-31 Kumamoto Technology & Industry Foundation 生体リズム障害の度合の判断方法
US20050137247A1 (en) 2003-12-22 2005-06-23 The Brigham And Women's Hospital, Inc. Methods and compositions for treatment of hypertension
CA2551637A1 (en) 2003-12-24 2005-07-14 Sepracor Inc. Melatonin combination therapy for improving sleep quality
GB0400031D0 (en) * 2004-01-03 2004-02-04 Univ Sheffield Depression treatment
CA2616177C (en) 2005-07-29 2012-05-01 Vanda Pharmaceuticals, Inc. Imidazolylalkyl-pyridines for the treatment of a sleep disorder
US7754902B2 (en) 2006-05-18 2010-07-13 Vanda Pharmaceuticals, Inc. Ruthenium(II) catalysts for use in stereoselective cyclopropanations
MX2008014840A (es) 2006-05-22 2008-12-05 Vanda Pharmaceuticals Inc Tratamiento de trastornos depresivos.
RU2488392C2 (ru) * 2006-05-22 2013-07-27 Ванда Фармасьютиклз, Инк. Лечение агонистом мелатонина
WO2008011150A1 (en) 2006-07-20 2008-01-24 Somaxon Pharmaceuticals, Inc. Methods of improving the pharmacokinetics of doxepin
ZA200900379B (en) 2006-07-21 2010-08-25 Univ California Human endogenous retrovirus polypeptide compositions and methods of use thereof
US20110077200A1 (en) 2006-12-06 2011-03-31 Somaxon Pharmaceuticals, Inc. Combination therapy using low-dose doxepin for the improvement of sleep
WO2008128049A2 (en) 2007-04-11 2008-10-23 Biomarin Pharmaceutical Inc. Methods of administering tetrahydrobiopterin, associated compositions, and methods of measuring
WO2009036257A1 (en) 2007-09-13 2009-03-19 Vanda Pharmaceuticals, Inc. Prediction of sleep parameter and response to sleep-inducing compound based on per3 vntr genotype
WO2009084023A2 (en) 2007-10-19 2009-07-09 Glenmark Generics Limited Amorphous ramelteon and process for the preparation thereof
EP2215073A4 (en) 2007-10-31 2011-04-06 Merck Sharp & Dohme SLEEP MODULATION WITH NR2B RECEPTOR ANTAGONISTS
JP5558016B2 (ja) 2009-03-17 2014-07-23 株式会社 資生堂 概日リズム調整剤
WO2010115615A1 (en) * 2009-04-07 2010-10-14 Duocort Pharma Ab Improved glucocorticoid therapy
US20120136050A1 (en) 2009-07-16 2012-05-31 Vanda Pharmaceuticals Inc. Use of a melatonin agonist for the treatment of sleep disorders including primary insomnia
US11918557B2 (en) 2012-01-26 2024-03-05 Vanda Pharmaceuticals Inc. Treatment of circadian rhythm disorders
WO2013112951A2 (en) 2012-01-26 2013-08-01 Vanda Pharmaceuticals Inc. Treatment of circadian rhythm disorders
BR112014028446A2 (pt) 2012-05-18 2017-10-24 Vanda Pharmaceuticals Inc composto isolado, composição farmacêutica, método de tratamento ou prevenção de pelo menos um de doenças, distúrbios ou condições seguintes, e, método de tratamento ou prevenção de um distúrbio de ritmo circadiano ou distúrbio com um componente circadiano em um indivíduo
KR102148990B1 (ko) 2012-12-18 2020-08-27 반다 파마슈티칼즈, 인코퍼레이티드. 일주기 리듬 장애의 치료
US10376487B2 (en) 2013-11-12 2019-08-13 Vanda Pharmaceuticals Inc. Method of treatment
JP6921534B2 (ja) 2014-02-12 2021-08-18 バンダ・ファーマシューティカルズ・インコーポレイテッドＶａｎｄａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． 高純度医薬品等級タシメルテオン

Also Published As

Publication number Publication date
CL2014001992A1 (es) 2015-03-13
JP2016172737A (ja) 2016-09-29
US20210161854A1 (en) 2021-06-03
SI2806863T1 (sl) 2017-12-29
US10980770B2 (en) 2021-04-20
DK2806863T3 (en) 2017-10-30
EP3300728A2 (en) 2018-04-04
AU2016204178A1 (en) 2016-07-14
CA3159064A1 (en) 2013-08-01
AU2016204217A1 (en) 2016-07-14
EP2806863A2 (en) 2014-12-03
US8785492B2 (en) 2014-07-22
CA2861108C (en) 2020-09-08
US20170100366A1 (en) 2017-04-13
JP7119261B2 (ja) 2022-08-17
US11633377B2 (en) 2023-04-25
CN104379135A (zh) 2015-02-25
KR102171965B1 (ko) 2020-10-30
US11826339B2 (en) 2023-11-28
KR102593047B1 (ko) 2023-10-24
US11285129B2 (en) 2022-03-29
AU2019204306A1 (en) 2019-07-04
EP2806863B1 (en) 2017-08-09
IL233715A0 (en) 2014-09-30
US10945988B2 (en) 2021-03-16
US20220168263A1 (en) 2022-06-02
AU2021204784B2 (en) 2024-11-14
IN2014DN07132A (https=) 2015-04-24
JP2020097602A (ja) 2020-06-25
CN104519877A (zh) 2015-04-15
AU2019203910A1 (en) 2019-06-20
KR20210118983A (ko) 2021-10-01
KR20180100450A (ko) 2018-09-10
CA3085116A1 (en) 2013-08-01
CO7131366A2 (es) 2014-12-01
JP2023071727A (ja) 2023-05-23
IN2014DN07050A (https=) 2015-04-10
US20220175716A1 (en) 2022-06-09
JP2022095662A (ja) 2022-06-28
CA3085116C (en) 2022-07-19
AU2018201909A1 (en) 2018-04-12
US10610510B2 (en) 2020-04-07
KR20220087582A (ko) 2022-06-24
CN111603460A (zh) 2020-09-01
US20150216837A1 (en) 2015-08-06
US9855241B2 (en) 2018-01-02
US9549913B2 (en) 2017-01-24
EP3620794A1 (en) 2020-03-11
US20190070144A1 (en) 2019-03-07
US9060995B2 (en) 2015-06-23
KR102411809B1 (ko) 2022-06-22
CN110215440A (zh) 2019-09-10
EP2806864B1 (en) 2021-08-25
BR112014018433A2 (https=) 2017-06-20
MX2014009078A (es) 2016-01-25
JP2019038822A (ja) 2019-03-14
CA2861111C (en) 2021-11-23
MX2020007448A (es) 2020-09-14
KR20190006598A (ko) 2019-01-18
ES2646197T3 (es) 2017-12-12
US20140296330A1 (en) 2014-10-02
CL2014001993A1 (es) 2015-03-13
IL269054A (en) 2019-10-31
CN104379135B (zh) 2020-07-14
KR20140116927A (ko) 2014-10-06
EP4502609A2 (en) 2025-02-05
RU2014134552A (ru) 2016-03-20
WO2013112949A2 (en) 2013-08-01
US11850229B2 (en) 2023-12-26
EP4502609A3 (en) 2025-04-09
EP2806864A2 (en) 2014-12-03
IL233714A0 (en) 2014-09-30
US11833130B2 (en) 2023-12-05
JP2017039731A (ja) 2017-02-23
USRE46604E1 (en) 2017-11-14
AU2013211878A1 (en) 2014-08-21
MX367184B (es) 2019-08-08
US20180071245A1 (en) 2018-03-15
US20210205261A1 (en) 2021-07-08
US10149829B2 (en) 2018-12-11
WO2013112951A2 (en) 2013-08-01
BR112014018429A2 (https=) 2017-06-20
US20140357710A1 (en) 2014-12-04
BR112014018433A8 (pt) 2017-07-11
US20240156775A1 (en) 2024-05-16
US20140296331A1 (en) 2014-10-02
KR102307012B1 (ko) 2021-09-30
RU2631602C2 (ru) 2017-09-25
KR101895653B1 (ko) 2018-09-05
CA2861111A1 (en) 2013-08-01
US20220168264A1 (en) 2022-06-02
CA2861108A1 (en) 2013-08-01
US11918556B2 (en) 2024-03-05
KR20170058463A (ko) 2017-05-26
RU2014134555A (ru) 2016-03-20
AU2019203910B2 (en) 2021-09-23
KR20200123873A (ko) 2020-10-30
US9539234B2 (en) 2017-01-10
US20250161259A1 (en) 2025-05-22
AU2021204784A1 (en) 2021-08-05
WO2013112951A3 (en) 2014-12-31
US20170087123A1 (en) 2017-03-30
JP2018080181A (ja) 2018-05-24
MX374068B (es) 2020-07-30
KR20200022543A (ko) 2020-03-03
JP2021073222A (ja) 2021-05-13
US20210330634A1 (en) 2021-10-28
ES2897671T3 (es) 2022-03-02
US12201604B2 (en) 2025-01-21
US20200179326A1 (en) 2020-06-11
WO2013112949A3 (en) 2013-09-19
US20140296332A1 (en) 2014-10-02
US20200009106A1 (en) 2020-01-09
RU2650647C2 (ru) 2018-04-16
HRP20171600T1 (hr) 2017-12-15
AU2018201302A1 (en) 2018-03-15
IL269041A (en) 2019-10-31
CO7131353A2 (es) 2014-12-01
JP2015509106A (ja) 2015-03-26
AU2013211880A1 (en) 2014-08-21
KR102317399B1 (ko) 2021-10-26
MX2014009079A (es) 2016-01-25
US10449176B2 (en) 2019-10-22
US20240197671A1 (en) 2024-06-20
KR20140117537A (ko) 2014-10-07
JP6267260B2 (ja) 2018-01-24
BR112014018429A8 (pt) 2017-07-11
MX2019012197A (es) 2020-08-31
KR20190069617A (ko) 2019-06-19
PT2806863T (pt) 2017-11-09
JP2015508157A (ja) 2015-03-16
EP3300728A3 (en) 2018-05-02
US20130197076A1 (en) 2013-08-01

Similar Documents

Publication Publication Date Title
US12201604B2 (en) Treatment of circadian rhythm disorders
US11918557B2 (en) Treatment of circadian rhythm disorders
US20240350451A1 (en) Treatment of circadian rhythm disorders